shstuebingen Current page: 2

Pharmaceutical company AMW recently announced that it has achieved a key milestone in opening up new markets within the European Union (EU) and beyond with the final report of the first Notified Body Opinion (NBO) for its goserelin implant. The active ingredient goserelin is a synthetic peptide that can be used primarily in the treatment […]

Since its foundation, the Austrian medical technology manufacturer Tyromotion has continuously brought new products to the market and established a well thought-out overall concept for neurorehabilitation with TYROTHERAPY. This concept has now been expanded to include a product series for medical training therapy (MTT-LINE), which optimally complements the existing product portfolio. In addition, June 2023 […]

The advantages of syndicates: SHS Capital’s healthcare specialisation in the cap table In the ever-evolving private equity landscape, there is an undeniable advantage in specialisation and syndication. At its core, healthcare is not just about investment and returns; it is a sector that requires a deep understanding of complex elements, from the latest technological breakthroughs […]

The German Private Equity Investor SHS Capital has completed the Final Closing of its sixth fund generation The targeted fund volume of EUR 200 million could significantly be overachieved with ca. EUR 270 million and is more than doubling the predecessor fund’s size The new fund will invest in European growing healthcare companies and allocates […]

SHS Capital has acquired a majority stake in the Baden-Württemberg-based robotics company ESSERT GmbH ESSERT develops intelligent automation solutions for a wide range of applications with a focus on the pharmaceutical, life science and general industrial sectors The company’s core product is the ESSERT MicroFactory, a modular production platform for the automation of low-volume, high-mix […]

Our investors, portfolio representatives, SHS senior advisors and healthcare experts were invited to the Hotel Krone in the centre of Tübingen. The day offered exciting presentations on healthcare investments and outlooks on economic developments and medical innovations in the coming years. Furthermore, four of the SHS portfolio companies gave exciting presentations about their companies and […]

Another format that SHS has specifically created for its portfolio companies is the SHS portfolio workshops. These take place quarterly, covering various topics. The aim is to discuss topics that concern a large proportion of the portfolio companies and to provide the companies the opportunity to exchange ideas and knowledge, to discuss approaches to solving […]

The new training and networking format is created for newer employees as well as current and former interns and is intended to provide practical insights into selected topics from the private equity industry. Speakers are both external and experienced SHS colleagues. For the first session, SHS managed to secure Sebastian Schreiber from SySS as external […]

Guillaume Balz joined the SHS team as Investment Manager in January 2023. After obtaining his Bachelor’s degree in Business and Economics in Dortmund and Athens, he completed his Master’s degree in Finance and Strategic Management in Copenhagen. He then decided to join Simon-Kucher, where he advised companies on marketing, sales, pricing and go-to-market. From the […]

Salvia BioElectronics, a pioneering Dutch company specialising in the treatment and cure of severe migraines, announced the successful first implantation of its paper-thin neuromodulation solution. Migraine is the most common cause of disability in people under 50 and affects one in seven people, mainly women. More than five percent of migraine patients suffer from chronic […]

French company PathoQuest has entered into a strategic partnership with Oxford Nanopore Technologies to bring to market the first sequencing-based quality control test for the genetic characterisation of biopharmaceuticals. Most biologics are produced using genetically modified cell lines. For many cell therapies, the product itself is a genetically modified cell line. Throughout the development of […]

You joined SHS this February to support the team in its market activities, especially in the areas of business development, communication and deal-sourcing. What was your motivation to work for SHS? With over 35 years of professional experience in M&A consulting and private equity, I have built a very extensive network of contacts and enjoy […]